Matthew E. Falagas
Adjunct Research Professor, Internal Medicine and Infectious Diseases
N/A
School of Medicine
Adjunct Research Faculty
Academic Qualifications
|
Qualification |
Year |
Awarding Institution |
Department |
Thesis title (Optional Entry) |
|
Certified Diplomate |
1996 |
Certified Diplomate in Infectious Diseases by the American Board of Internal Medicine (committee of Infectious Diseases) (USA) |
American Board of Internal Medicine (committee of Infectious Diseases) (USA) |
|
|
Certified Diplomate |
1993 |
Certified Diplomate in Internal Medicine by the American Board of Internal Medicine (USA) |
American Board of Internal Medicine (USA) |
|
|
DSc |
1999 |
Athens University |
School of Medicine |
The impact of cytomegalovirus (CMV) on short and long term survival of orthotopic liver transplant recipients |
|
MSc |
1996 |
Harvard University |
Harvard School of Public Health (Epidemiology) |
|
|
MD |
1986 |
Athens University |
School of Medicine |
|
Employment History
|
Period of employment |
Employer |
Location |
Position |
|
|
From |
To |
|||
|
02/2005 |
continuing |
Alfa Institute of Biomedical Sciences (AIBS) |
Athens, Greece |
Director |
|
02/2006 |
continuing |
Tufts University School of Medicine |
Boston, Massachusetts, USA |
Adjunct Associate Professor of Medicine |
|
03/2021 |
continuing |
Hygeia Hospital |
Athens, Greece |
Director, First Department of Internal Medicine |
Publications
|
Ref. Number |
Year |
Title |
Other authors |
Journal and Publisher / |
Vol. |
Pages |
|
|
2024
|
Pseudomonas and related Gram-negative bacillary infections. [In the textbook Goldman-Cecil Medicine (27th edition)]. |
Falagas ME, Rafailidis PI |
Saunders, Elsevier, Philadelphia, Pennsylvania |
2 |
1968-1973 |
|
|
2020 |
Pseudomonas and related Gram-negative bacillary infections. [In the textbook Goldman-Cecil Medicine (26th edition)]. |
Falagas ME, Rafailidis PI |
Saunders, Elsevier, Philadelphia, Pennsylvania |
2 |
1931-1936 |
|
|
2018 |
Prolonged versus short-term intravenous infusion of antipseudomonal β-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials. |
Vardakas KZ, Voulgaris GL, Maliaros A, Samonis G, Falagas ME |
Lancet Infectious Diseases (Elsevier, Amsterdam, Netherlands) |
18 |
108-120 |
|
|
2017 |
Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals. |
Falagas ME, Skalidis T, Vardakas KZ, Legakis NJ, Hellenic Cefiderocol Study Group |
Journal of Antimicrobial Chemotherapy (Oxford University Press, UK) |
72 |
1704-1708 |
|
|
2012 |
Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions. |
Magiorakos A, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, et al |
Clinical Microbiology and Infection (European Society of Clinical Microbiology and Infectious Diseases) |
18 |
268-281 |
|
|
2012 |
Gorbach’s 5-Minute Infectious Diseases Consult, 2nd edition. |
Falagas ME, Mylonakis E |
Williams & Wilkins, Philadephia, Pensylvania |
Editor of the book |
Entire book |
|
|
2010 |
Adjustment of dosing of antimicrobial agents for bodyweight in adults. |
Falagas ME, Karageorgopoulos DE |
Lancet (Elsevier, Amsterdam, Netherlands) |
375 |
248-251 |
|
|
2010 |
Fosfomycin for the treatment of multidrug-resistant, including ESBL-producing, Enterobacteriaceae infections: a systematic review of microbiological and clinical studies. |
Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos DE |
Lancet Infectious Diseases (Elsevier, Amsterdam, Netherlands) |
10 |
43-50 |
|
|
2009 |
Meta-analysis in infectious diseases |
Falagas ME, Leibovici L |
Elsevier, Amsterdam, Netherlands |
Editor of the book |
Entire book |
|
|
1999 |
Guidelines for Infectious Diseases in Primary Care |
Gorbach SL, Bartlett JG, Falagas ME, Hamer D |
Lippincott Williams and Wilkins, Philadephia, Pensylvania |
Editor of the book |
Entire book |
Exhibitions
|
Ref. Number |
Date |
Topic |
International / Local |
Location* |
Role in Exhibition |
|
|
12/2023 |
19th Top-10 on Infections (seminar on infectious diseases that is organized yearly during the last 19 years) |
Local |
Athens, Greece |
Organizer |
|
|
12/2022 |
18th Top-10 on Infections (seminar) |
Local |
Athens, Greece |
Organizer |
|
|
04/2012 |
Current treatment of common diseases in women (seminar) |
Local |
Nafplio, Greece |
Organizer and director |
|
|
04/2011 |
Recent developments on prulifloxacin (seminar) |
Local |
Nafplio, Greece |
Organizer and director |
|
|
03/2010 |
Antibiotics in clinical practice (seminar) |
Local |
Loutraki, Greece |
Co-organizer and director |
|
|
11/2009 |
Epidemic and endemic influenza (seminar) |
Local |
Athens, Greece |
Organizer and director |
|
|
10/2007 |
Respiratory infections (seminar) |
Local |
Athens, Greece |
Co-organizer and director |
|
|
09/2005 |
4th conference of the International Society for the Prevention of Tobacco Induced Diseases (ISPTID) |
International |
Athens, Greece |
Local organizer and co-chair of the Scientific Committee |
|
|
06/2004 |
3rd Summer School of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) |
International |
Athens, Greece |
Local organizer and course director |
|
|
10/2003 |
Obesity and complications: Inter-University European seminar |
International |
Athens, Greece |
Local organizer and course director |
Research Projects
|
Ref. Number |
Date |
Title |
Funded by |
Project Role* |
|
|
2020-2022 |
Intravenous fosfomycin for the treatment of patients with bone and joint infections |
InfectoPharm, Germany |
Principal investigator |
|
|
2019-2020 |
Clinical use of intravenous polymyxin B for the treatment of patients with multidrug-resistant Gram-negative bacterial infections |
InfectoPharm, Germany |
Principal investigator |
|
|
2016-2019 |
European prospective cohort study on enterobacteriaeae with resistance to carbapenems (EURECA) |
European Commission |
Site principal investigator |
|
|
2017-2018 |
In vitro antibacterial activity of TP-6076 against clinical strains collected from inpatients in Greek hospitals |
Tetraphase, USA |
Principal investigator |
|
|
2016-2017 |
In vitro antibacterial activity of cefiderocol (S-649266) against clinical strains collected from inpatients in Greek hospitals |
Shionogi, Japan |
Principal investigator |
|
|
2015-2016 |
A multicenter, randomized, double-blind, comparative study to evaluate the safety and efficacy of ZTI-01 versus piperacillin/tazobactam in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults |
Zavante, USA |
Site principal investigator |
|
|
2012-2014 |
Antimicrobial activity of prulifloxacin |
Angelini, Italy |
Principal investigator |
|
|
2010-2011 |
Evaluation of the pharmacokinetic and pharmacodynamic properties and activity of trimethoprim-sulfametrol against pathogens |
Rokitan, Austria |
Principal investigator |
|
|
2006-2008 |
Health literacy - informed consent |
Cordis, European Commission |
Co-investigator |
|
|
2004-2005 |
Biomedical research productivity of European countries |
Swiss Secretariat for Education, Research and Innovation |
Principal investigator |
Academic Consulting Services/Councils/Boards/Editorial Committees
|
Ref. Number |
Period |
Organization |
Title of Position or Service |
Key Activities |
|
|
2020-2021 |
Scientific Committee, Henry Dunant Hospital Center, Athens, Greece |
President |
Review and decisions on various scientific issues related to the function of the hospital |
|
|
2007-2012 |
Professional Affairs Advisory Committee (Infectious Diseases) |
European Society of Clinical Microbiology and Infectious Diseases (ESCMID) |
Review and decisions on various professional issues in the field of infectious diseases |
|
|
2008-2010 |
ECDC-CDC task force on definitions of multidrug-resistant Gram-negative bacilli |
ECDC-CDC (European Center for Disease Prevention and Control - Center for Disease Prevention and Control) |
Review of scientific data and decisions on definitions of multidrug resistant (MDR), extensively drug resistant (XDR) and pandrug resistant (PDR) Gram-negative bacilli |
|
|
2019-continuing |
Expert Review of Anti-Infective Therapy (ERAIT) |
Editorial board |
Editorial decisions about acceptance/rejection of submitted articles and consulting on the scientific content of the journal |
|
|
2011-continuing |
Medscape Infectious Diseases |
Advisory board |
Consulting on the scientific content |
Awards/International Recognition
|
Ref. Number |
Date |
Title |
Awarded by: |
|
|
2023 |
Inclusion in the list of the top-20 most highly cited researchers in Internal Medicine globally (data from ScholarGPS) |
ScholarGPS |
|
|
2023 |
Most highly cited scholar in the field of Microbiology in Greece (data from Research Gate) |
Research Gate |
|
|
2022 |
Ranked # 2 most highly cited scholar of all scientific fields in Greece (data from Research.com) |
Research.com |
|
|
2018 |
Inclusion in the list of the top-10 most highly cited researchers of all scientific fields in Greece (data from Thomson Reuters) |
Thomson Reuters |
|
|
2017 |
ESCMID Fellow |
European Society of Clinical Microbiology and Infectious Diseases (ESCMID) |
|
|
1997 |
Maxwell Finland Young Investigator Award for Excellence in Research |
Massachusetts Infectious Diseases Society |
|
|
1994 |
Edward Kass Award for Clinical Excellence |
Massachusetts Infectious Diseases Society |
|
|
1992 |
House Staff Award for Excellence in Teaching |
The Medical Student Body, State University of New York (SUNY) at Buffalo, School of Medicine and Biomedical Sciences, Buffalo, New York |
|
|
1986 |
Diploma in Medicine with “Excellence” (Top 1% of class) |
Athens University School of Medicine |
|
|
1980 |
First Prize, Greek National Mathematics Competition |
Greek Association of Mathematicians |